(0.17%) 5 108.65 points
(0.14%) 38 293 points
(0.20%) 15 960 points
(-1.11%) $82.92
(4.84%) $2.02
(0.12%) $2 350.00
(0.09%) $27.56
(4.11%) $960.00
(-0.17%) $0.933
(-0.28%) $10.99
(-0.45%) $0.797
(1.73%) $93.46
@ CNY10.28
发出时间: 15 Feb 2024 @ 04:48
回报率: -0.29%
上一信号: Feb 15 - 02:13
上一信号:
回报率: -0.48 %
Live Chart Being Loaded With Signals
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China...
Stats | |
---|---|
今日成交量 | 6.37M |
平均成交量 | 1.46M |
市值 | 989.87M |
EPS | CNY0 ( 2024-03-11 ) |
下一个收益日期 | ( CNY0 ) 2024-05-13 |
Last Dividend | CNY0 ( N/A ) |
Next Dividend | CNY0 ( N/A ) |
P/E | -10.57 |
ATR14 | CNY0.215 (2.10%) |
音量 相关性
Gracell Biotechnologies 相关性 - 货币/商品
Gracell Biotechnologies 财务报表
Annual | 2022 |
营收: | CNY0 |
毛利润: | CNY0 (0.00 %) |
EPS: | CNY-5.65 |
FY | 2022 |
营收: | CNY0 |
毛利润: | CNY0 (0.00 %) |
EPS: | CNY-5.65 |
FY | 2021 |
营收: | CNY366 000 |
毛利润: | CNY0.00 (0.00 %) |
EPS: | CNY-4.31 |
FY | 2020 |
营收: | CNY0.00 |
毛利润: | CNY0.00 (0.00 %) |
EPS: | CNY-13.85 |
Financial Reports:
No articles found.
Gracell Biotechnologies
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。